Literature DB >> 9657259

Overexpression of cardiotrophin-1 and gp130 during experimental acute Chagasic cardiomyopathy.

B Chandrasekar1, P C Melby, D Pennica, G L Freeman.   

Abstract

Cardiotrophin-1 (CT-1), a cytokine with structural similarities to interleukin-6, has been shown to signal through gp130-dependent pathways. In vitro, CT-1 promotes the survival and induces hypertrophy of neonatal cardiomyocytes. Since acute Chagas' disease involves an inflammatory response followed by chamber dilation, with subsequent compensatory hypertrophy, we hypothesized CT-1 and gp130 may participate in this disease process. Thus, we investigated expression and localization of these moieties during acute Chagasic cardiomyopathy. Lewis rats (n = 6/group) were either inoculated with cell culture-derived T. cruzi trypomastigotes or saline, and sacrificed 15 days later. Hearts were collected for histology, immunohistochemistry (IHC), mRNA, and protein analyses. Histology showed dense myocardial infection with amastigotes and diffuse mononuclear cell infiltrate. Northern blot analysis showed low level expression of CT-1 mRNA in controls, which was markedly elevated in infected animals (2.5-fold; P < 0.001). Similarly, Western blotting showed a twofold elevation of CT-1 protein in infected animals (P < 0.025). Likewise, levels of both gp130 mRNA and protein were low in controls, but were approximately threefold higher in infected animals. IHC showed weak and diffuse staining for CT-1 in control myocardium, while intense staining especially localized to the cytoplasmic region of cardiomyocytes, was found in infected animals. Although gp130 immunoreactivity was observed in both normal and infected myocardium, more intense staining was found in infected animals. Unlike CT-1, gp130 staining was granular, and was present in both the cytoplasm as well as in the perinuclear region. These data suggest that there is substantial overexpression of both CT-1 and gp130 in the heart during acute Chagasic carditis. Their overexpression may provide a mechanism for myocyte protection, and for development of compensatory cardiac hypertrophy following myocardial damage in this form of cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657259     DOI: 10.1016/s0165-2478(97)00167-3

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  6 in total

Review 1.  Cardiotrophin-1 (CT-1): a novel hypertrophic and cardioprotective agent.

Authors:  D S Latchman
Journal:  Int J Exp Pathol       Date:  1999-08       Impact factor: 1.925

2.  Toll-like receptor 2 regulates interleukin-1beta-dependent cardiomyocyte hypertrophy triggered by Trypanosoma cruzi.

Authors:  Christine A Petersen; Katherine A Krumholz; Barbara A Burleigh
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Differential regulation of nitric oxide synthase isoforms in experimental acute chagasic cardiomyopathy.

Authors:  B Chandrasekar; P C Melby; D A Troyer; G L Freeman
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

4.  Role for interleukin-1 beta in Trypanosoma cruzi-induced cardiomyocyte hypertrophy.

Authors:  Christine A Petersen; Barbara A Burleigh
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

5.  Trypanosoma cruzi Promotes Transcriptomic Remodeling of the JAK/STAT Signaling and Cell Cycle Pathways in Myoblasts.

Authors:  Lindice M Nisimura; Laura L Coelho; Tatiana G de Melo; Paloma de Carvalho Vieira; Pedro H Victorino; Luciana R Garzoni; David C Spray; Dumitru A Iacobas; Sanda Iacobas; Herbert B Tanowitz; Daniel Adesse
Journal:  Front Cell Infect Microbiol       Date:  2020-06-17       Impact factor: 5.293

Review 6.  The Role of Interleukin-6 Family Members in Cardiovascular Diseases.

Authors:  Yongqi Feng; Di Ye; Zhen Wang; Heng Pan; Xiyi Lu; Menglong Wang; Yao Xu; Junping Yu; Jishou Zhang; Mengmeng Zhao; Shuwan Xu; Wei Pan; Zheng Yin; Jing Ye; Jun Wan
Journal:  Front Cardiovasc Med       Date:  2022-03-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.